MannKind | MNKD - Umlaufvermögen





Umlaufvermögen Veränderung Datum
Adma Biologics USD 575.86M 47.66M 2026-09
BioCryst Pharmaceuticals USD 531.15M 46.47M 2026-09
Eli Lilly USD 65.26B 591M 2026-09
Halozyme Therapeutics USD 1.85B 913.71M 2026-09
Insmed USD 1.71B 72.59M 2026-09
Karyopharm Therapeutics USD 126.33M 23.19M 2026-03
MacroGenics USD 321.69M 139.16M 2026-06
MannKind USD 240.48M 5.24M 2026-09
Merck USD 38.94B 2.26B 2026-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Novavax USD 707.96M 63.14M 2026-09
Novo Nordisk DKK 31.89B 145.42B 2026-06
Pfizer USD 45.01B 3.65B 2026-09
Sanofi EUR 33.21B 1.68B 2026-09
Xencor USD 498.66M 24.55M 2026-09